Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Medical Director Study Director Merck Sharp & Dohme LLC
Kontakt
Toll Free Number Kontakt: Phone: 1-888-577-8839 E-Mail: Trialsites@merck.com» Kontaktdaten anzeigen
Studienlocations (3 von 130)
The University of Arizona Cancer Center - North Campus ( Site 0011) 85721 Tucson United StatesAbgeschlossen» Google-MapsSt Joseph Heritage Healthcare-Oncology ( Site 0056) 92835 Fullerton United StatesAbgeschlossen» Google-MapsCedars Sinai Medical Center ( Site 0002) 90048 Los Angeles United StatesAbgeschlossen» Google-Maps
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) 94158 San Francisco United StatesAbgeschlossen» Google-MapsRocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) 80045 Aurora United StatesAbgeschlossen» Google-MapsWinship Cancer Institute of Emory University ( Site 0025) 30322-1013 Atlanta United StatesAbgeschlossen» Google-MapsAugusta University ( Site 0028) 30912 Augusta United StatesAbgeschlossen» Google-MapsMarkey Cancer Center ( Site 0018) 40536 Lexington United StatesAbgeschlossen» Google-MapsUniversity of Maryland ( Site 0050) 21201 Baltimore United StatesRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 410-328-7224» Ansprechpartner anzeigenWeinberg Cancer Institute at Franklin Square ( Site 0054) 21237 Baltimore United StatesAbgeschlossen» Google-MapsUniversity of Massachusetts ( Site 0017) 01655 Worcester United StatesAbgeschlossen» Google-MapsHenry Ford Health System ( Site 0060) 48202 Detroit United StatesAbgeschlossen» Google-MapsCancer Partners of Nebraska ( Site 0051) 68510 Lincoln United StatesAbgeschlossen» Google-MapsMemorial Sloan Kettering Cancer Center- Monmouth ( Site 0116) 07748 Middletown United StatesRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 646-888-5089» Ansprechpartner anzeigenMemorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126) 10604 Harrison United StatesRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 646-888-5089» Ansprechpartner anzeigenVA New York Harbor Healthcare System Manhattan ( Site 0094) 10010 New York United StatesAbgeschlossen» Google-MapsLaura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057) 10016 New York United StatesAbgeschlossen» Google-MapsMemorial Sloan Kettering Cancer Center ( Site 0026) 10065 New York United StatesRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 646-888-5089» Ansprechpartner anzeigenSouthwestern Regional Medical Center, Inc. ( Site 0079) 74133 Tulsa United StatesAbgeschlossen» Google-MapsEastern Regional Medical Center, Inc. ( Site 0077) 19124 Philadelphia United StatesAbgeschlossen» Google-MapsSanford Hematology Oncology-Sioux Falls SD ( Site 0012) 57104 Sioux Falls United StatesAbgeschlossen» Google-MapsIntermountain Healthcare ( Site 0043) 84790 Saint George United StatesAbgeschlossen» Google-MapsVirginia Mason Medical Center ( Site 0052) 98101 Seattle United StatesAbgeschlossen» Google-MapsVeterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093) 98108 Seattle United StatesRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 206-277-3101» Ansprechpartner anzeigenCentro de Oncologia e Investigacion Buenos Aires COIBA ( Site 2703) B1884BBF Berazategui ArgentinaAbgeschlossen» Google-MapsHospital Britanico de Buenos Aires ( Site 2704) C1280AEB Ciudad de Buenos Aires ArgentinaAbgeschlossen» Google-MapsInstituto de Investigaciones Metabolicas ( Site 2700) C1012AAR Buenos Aires ArgentinaAbgeschlossen» Google-MapsHospital Aleman ( Site 2702) C1118AAT Buenos Aires ArgentinaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +54 11 4827-7000» Ansprechpartner anzeigenKinghorn Cancer Centre ( Site 2200) 2010 Darlinghurst AustraliaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +61293555655» Ansprechpartner anzeigenMNCCI Port Macquarie Base Hospital ( Site 2201) 2444 Port Macquarie AustraliaAbgeschlossen» Google-MapsLinear Clinical Research Ltd ( Site 2202) 6009 Nedlands AustraliaAbgeschlossen» Google-MapsSunnybrook Research Institute ( Site 0210) M4N 3M5 Toronto CanadaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 4164805000» Ansprechpartner anzeigenHopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0203) H1T 2M4 Montreal CanadaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: 51425234005853» Ansprechpartner anzeigenJewish General Hospital ( Site 0209) H3T 1E2 Montreal CanadaAbgeschlossen» Google-MapsCentre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 G1J 1Z4 Quebec CanadaAbgeschlossen» Google-MapsFundacion Centro de Investigacion Clinica CIC ( Site 2812) 050021 Medellin ColombiaAbgeschlossen» Google-MapsRodrigo Botero SAS ( Site 2801) 050030 Medellin ColombiaAbgeschlossen» Google-MapsBiomelab S A S ( Site 2800) 080001 Barranquilla ColombiaAbgeschlossen» Google-MapsSociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2808) 200001 Valledupar ColombiaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +5755602310» Ansprechpartner anzeigenOncomedica S.A. ( Site 2806) 230002 Monteria ColombiaAbgeschlossen» Google-MapsAdministradora Country SA - Clinica del Country ( Site 2802) 110221 Bogota ColombiaAbgeschlossen» Google-MapsClinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2807) 110311 Bogota ColombiaAbgeschlossen» Google-MapsInstituto Nacional de Cancerologia E.S.E ( Site 2809) 111511 Bogota ColombiaAbgeschlossen» Google-MapsC. Medico Imbanaco Cali S.A. ( Site 2810) 760042 Cali ColombiaAbgeschlossen» Google-MapsRigshospitalet ( Site 0402) 2100 Copenhagen DenmarkAbgeschlossen» Google-MapsHerlev og Gentofte Hospital. ( Site 0401) 2730 Herlev DenmarkRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +45 38 68 38 68» Ansprechpartner anzeigenOdense Universitetshospital ( Site 0400) 5000 Odense DenmarkAbgeschlossen» Google-MapsCHU Poitiers ( Site 0612) 86021 Poitiers FranceAbgeschlossen» Google-MapsCentre Antoine Lacassagne ( Site 0610) 06189 Nice FranceAbgeschlossen» Google-MapsInstitut de Cancerologie Strasbourg Europe ( Site 0613) 67200 Strasbourg FranceRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +33388252485» Ansprechpartner anzeigenCentre Georges Francois Leclerc ( Site 0608) 21000 Dijon FranceAbgeschlossen» Google-MapsInstitut Bergonie ( Site 0603) 33076 Bordeaux FranceAbgeschlossen» Google-MapsInstitut Gustave Roussy ( Site 0601) 94805 Villejuif FranceRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +33142114296» Ansprechpartner anzeigenCentro Regional de Sub Especialidades Medicas SA ( Site 3003) 09001 Guatemala GuatemalaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +50259450559» Ansprechpartner anzeigenCentro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 3004) 01010 Guatemala GuatemalaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +50259458053» Ansprechpartner anzeigenIntegra Cancer Institute ( Site 3006) 01010 Guatemala GuatemalaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +50222790939» Ansprechpartner anzeigenGrupo Angeles SA ( Site 3001) 01015 Guatemala GuatemalaRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +50240492110» Ansprechpartner anzeigenMater Misericordiae University Hospital ( Site 1654) D07 WKW8 Dublin IrelandAbgeschlossen» Google-MapsBon Secours Hospital ( Site 1656) T12 DV56 Cork IrelandAbgeschlossen» Google-MapsSt. Vincent's University Hospital ( Site 1653) 00004 Dublin IrelandRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +35314144259» Ansprechpartner anzeigenTallaght University Hospital ( Site 1652) D24 NROA Dublin IrelandAbgeschlossen» Google-MapsSoroka Medical Center ( Site 0800) 8457108 Beer-Sheva IsraelAbgeschlossen» Google-MapsRambam Health Care Campus-Oncology Division ( Site 0801) 3109601 Haifa IsraelAbgeschlossen» Google-MapsHadassah Ein Kerem Medical Center ( Site 0802) 9112001 Jerusalem IsraelAktiv, nicht rekrutierend» Google-MapsChaim Sheba Medical Center ( Site 0803) 5262000 Ramat Gan IsraelRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +97235302243» Ansprechpartner anzeigenSourasky Medical Center ( Site 0804) 6423906 Tel Aviv IsraelAbgeschlossen» Google-MapsIstituto Nazionale Tumori Fondazione Pascale ( Site 0700) 80131 Napoli ItalyAbgeschlossen» Google-MapsIstituto Clinico Humanitas Research Hospital ( Site 0703) 20089 Rozzano ItalyAbgeschlossen» Google-MapsPoliclinico Le Scotte di Siena ( Site 0704) 53100 Siena ItalyAbgeschlossen» Google-MapsAichi Cancer Center Hospital ( Site 2602) 464-8681 Nagoya JapanAktiv, nicht rekrutierend» Google-MapsNational Cancer Center Hospital East ( Site 2600) 2778577 Kashiwa JapanAktiv, nicht rekrutierend» Google-MapsKyoto University Hospital ( Site 2603) 606-8507 Kyoto-shi JapanAbgeschlossen» Google-MapsOsaka University Hospital ( Site 2604) 565-0871 Suita JapanAbgeschlossen» Google-MapsNational Cancer Center Hospital ( Site 2601) 104-0045 Tokyo JapanAktiv, nicht rekrutierend» Google-MapsThe Cancer Institute Hospital of JFCR ( Site 2605) 135-8550 Tokyo JapanAbgeschlossen» Google-MapsSeoul National University Bundang Hospital ( Site 2402) 13620 Seongnam-si Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +82317877022» Ansprechpartner anzeigenSeoul National University Hospital ( Site 2401) 03080 Seoul Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +82220720850» Ansprechpartner anzeigenSeverance Hospital Yonsei University Health System ( Site 2400) 03722 Seoul Korea, Republic ofAbgeschlossen» Google-MapsActualidad Basada en la Investigacion del Cancer ( Site 2903) 44680 Guadalajara MexicoRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +523313141707» Ansprechpartner anzeigenUnidad Biomedica Avanzada Monterrey S. A. ( Site 2902) 64460 Monterrey MexicoAbgeschlossen» Google-MapsCuidados Oncologicos ( Site 2908) 76000 Santiago De Quetaro MexicoAbgeschlossen» Google-MapsCentro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 2901) 89440 Madero MexicoAbgeschlossen» Google-MapsCentro Estatal de Cancerologia de Chihuahua ( Site 2907) 31000 Chihuahua MexicoAbgeschlossen» Google-MapsCRYPTEX Investigacion Clinica S.A. de C.V. ( Site 2900) 06100 Mexico City MexicoRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +525555743589» Ansprechpartner anzeigenCENEIT Oncologicos ( Site 2904) 03100 Mexico MexicoRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +5215529009882» Ansprechpartner anzeigenOaxaca Site Management Organization S.C. ( Site 2905) 68000 Oaxaca MexicoAbgeschlossen» Google-MapsHospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102) 13006 Trujillo PeruRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +51964820298» Ansprechpartner anzeigenInstituto Nacional de Enfermedades Neoplasicas ( Site 3106) 15038 Lima PeruAbgeschlossen» Google-MapsHospital Nacional Guillermo Almenara Irigoyen ( Site 3107) 15033 Lima PeruAbgeschlossen» Google-MapsClinica Internacional Sede San Borja ( Site 3100) 15036 Lima PeruRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +51999611475» Ansprechpartner anzeigenInstituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 3101) 15036 Lima PeruRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +5112241598 Ext.121» Ansprechpartner anzeigenOncosalud-Clinical Research ( Site 3108) 15036 Lima PeruRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +51971232095» Ansprechpartner anzeigenHospital Central de la Fuerza Aerea del Peru ( Site 3104) 15046 Lima PeruAbgeschlossen» Google-MapsHospital Militar Central Coronel Luis Arias Schereiber ( Site 3105) 15076 Lima PeruRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +51997468543» Ansprechpartner anzeigenHospital Arzobispo Loayza ( Site 3103) 15082 Lima PeruAbgeschlossen» Google-MapsS.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102) 410469 Oradea RomaniaAbgeschlossen» Google-MapsMedisprof ( Site 1107) 400641 Cluj Napoca RomaniaAbgeschlossen» Google-MapsSC Radiotherapy Center Cluj SRL ( Site 1105) 407280 Comuna Floresti RomaniaAbgeschlossen» Google-MapsS.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103) 200542 Craiova RomaniaAbgeschlossen» Google-MapsSpitalul PDR Medlife ( Site 1106) 500152 Brasov RomaniaAbgeschlossen» Google-MapsS.C.Focus Lab Plus S.R.L ( Site 1101) 022548 Bucuresti RomaniaAbgeschlossen» Google-MapsS.C.Gral Medical S.R.L ( Site 1104) 031422 Bucuresti RomaniaAbgeschlossen» Google-MapsArkhangelsk Clinical Oncological Dispensary ( Site 1204) 163045 Arkhangelsk Russian FederationAbgeschlossen» Google-MapsChelyabinsk Regional Clinical Oncological Dispensary ( Site 1212) 454087 Chelyabinsk Russian FederationSchwebend» Google-MapsMEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216) 143442 Krasnogorsk Russian FederationAbgeschlossen» Google-MapsN.N. Blokhin NMRCO ( Site 1201) 115477 Moscow Russian FederationAbgeschlossen» Google-MapsMSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1213) 125284 Moscow Russian FederationSchwebend» Google-MapsRyazan Regional Clinical Oncology dispensary ( Site 1202) 390011 Ryazan Russian FederationAbgeschlossen» Google-MapsSBHI Samara Regional Clinical Oncology Dispensary ( Site 1211) 443031 Samara Russian FederationAbgeschlossen» Google-MapsScientific Research Oncology Institute n.a. N.N.Petrov ( Site 1208) 197758 Saint Petersburg Russian FederationAbgeschlossen» Google-MapsClinical Hospital Saint Luka ( Site 1205) 194044 Saint-Petersburg Russian FederationAbgeschlossen» Google-MapsSBHI Leningrad Regional Clinical Hospital ( Site 1206) 194291 St.Petersburg Russian FederationAbgeschlossen» Google-MapsRepublican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1207) 420029 Kazan Russian FederationSchwebend» Google-MapsHospital Universitario Quiron Madrid ( Site 1352) 28223 Pozuelo de Alarcon SpainRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +34914521987» Ansprechpartner anzeigenHospital Universitari Vall d Hebron ( Site 1350) 08035 Barcelona SpainRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +34934894158» Ansprechpartner anzeigenUniversitaetsspital Zuerich ( Site 1400) 8091 Zuerich SwitzerlandAbgeschlossen» Google-MapsHopitaux Universitaires de Geneve HUG. ( Site 1406) 1211 Geneva SwitzerlandAbgeschlossen» Google-MapsOspedale Regionale di Bellinzona e Valli ( Site 1407) 6500 Bellinzona SwitzerlandRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +41918118194» Ansprechpartner anzeigenNecmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1507) 42080 Konya TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +903322237000» Ansprechpartner anzeigenBaskent University Adana Training Hospital ( Site 1508) 01250 Adana TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +905353067506» Ansprechpartner anzeigenHacettepe Universitesi Tıp Fakultesi ( Site 1503) 06100 Ankara TurkeyAbgeschlossen» Google-MapsAkdeniz Universitesi Tip Fakultesi ( Site 1504) 07070 Antalya TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +905052312377» Ansprechpartner anzeigenTrakya Universitesi Tip Fakultesi ( Site 1500) 22030 Edirne TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +905322480988» Ansprechpartner anzeigenIstanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1505) 34098 Istanbul TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +905052312377» Ansprechpartner anzeigenGöztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1506) 34722 Istanbul TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +902165664000» Ansprechpartner anzeigenEge Universitesi Tip Fakultesi ( Site 1502) 35100 Izmir TurkeyRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +902323903911» Ansprechpartner anzeigenChurchill Hospital ( Site 1606) OX3 7LE Oxford United KingdomAbgeschlossen» Google-MapsChristie NHS Foundation Trust ( Site 1601) M20 4BX Manchester United KingdomAbgeschlossen» Google-MapsNorthern Centre for Cancer Care ( Site 1602) NE7 7DN Newcastle Upon Tyne United KingdomRekrutierend» Google-Maps Ansprechpartner: Study Coordinator Phone: +441912138476» Ansprechpartner anzeigenWeston Park Hospital ( Site 1607) S10 2SJ Sheffield United KingdomAbgeschlossen» Google-Maps
1. Objective Response Rate (ORR) (Time Frame - Up to 53 months): ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors 1.1, modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ (modified RECIST 1.1). For participants with prostate cancer, ORR will be based on Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 as assessed by BICR.
Secondary outcome:
1. Duration of Response (DOR) (Time Frame - Up to 53 months): DOR is defined as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurs first. DOR will be assessed by BICR according to either modified RECIST 1.1 or PCWG-modified RECIST 1.1 for participants with prostate cancer.
2. Overall Survival (OS) (Time Frame - Up to 53 months): OS is defined as the time from the date of the first dose to the date of death due to any cause.
3. Progression Free Survival (PFS) (Time Frame - Up to 53 months): PFS is defined as the time from the date of the first dose to either: 1) the first documented disease progression as assessed either by BICR according to modified RECIST 1.1 or PCWG-modified RECIST 1.1 for participants with prostate cancer; or 2) death due to any cause, whichever occurs first.
4. Number of Participants Experiencing an Adverse Event (AE) (Time Frame - Up to 53 months): An AE is any unfavorable and unintended sign, symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE will be assessed.
5. Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE) (Time Frame - Up to 52 months): The number of participants discontinuing study treatment due to an AE will be assessed.
6. Objective Response Rate (ORR) in Participants with HRRm or HRD Positive Cancer (Time Frame - Up to 53 months): For participants with homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD) positive cancer, the ORR will be assessed. ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors 1.1, modified to follow a maximum of 10 target lesions in total and a maximum of 5 target lesions per organ (modified RECIST 1.1). For participants with prostate cancer, ORR will be based on Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 as assessed by BICR.
7. Time to Earliest Progression by Cancer Antigen-125 (CA-125) (Time Frame - Up to 53 months): For participants with BRCA1/2 non-mutated ovarian cancer only, the time to earliest progression by CA-125 will be assessed. Progression by CA-125 is defined as an increase in CA-125 level ≥2x upper limit normal (ULN) on 2 occasions, 1 week apart. For participants with elevated CA-125 (≥ULN) at baseline, progression by CA-125 is defined as an increase in CA-125 level ≥2x the nadir value on 2 occasions, 1 week apart.
8. Prostate-specific Antigen (PSA) Response Rate in Participants with Prostate Cancer (Time Frame - Up to 53 months): For participants with prostate cancer, the PSA response rate will be presented. PSA response rate is defined as the percentage of participants in the analysis population with PSA reduction of ≥50% from baseline measured twice at least 3 weeks apart.
9. Progression-Free Survival After Next-Line Treatment in Participants with sBRCAm Breast Cancer (Time Frame - Up to 53 months): For participants with somatic BRCA mutated (sBRCAm) breast cancer, the PFS after next-line treatment will be presented. PFS is defined as the time from the date of the first dose to either: 1) the first documented disease progression on the next-line of treatment, as assessed by BICR according to modified RECIST 1.1; or 2) death due to any cause, whichever occurs first.
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!